Covered, compounding — income-light. A 0.69% yield is low for an income card, but it is covered several times over: $0.40 a quarter on a 26.2% payout, with most of the life-sciences and diagnostics cash flow kept for acquisitions and reinvestment. Q3 2026 revenue grew 8.3% to $6.55 billion with $2.11 of earnings per share, so this is a compounding card, not a current-income card.
Key risk: Life-sciences demand swings — diagnostics and bioprocessing orders follow research budgets and customer inventory cycles, and a new chief executive took over in early October 2026, so execution under new leadership is unproven at this scale.
Changes if: the payout climbs toward 50% of earnings, or free cash flow stops covering the dividend several times over. Coverage depth, not the yield itself, is the tripwire here.
- ✓Payout-coverage check: 26.2% of earnings per MarketBeat — $1.60 indicated, with about 14% of cash flow going to dividends. A wide cushion; most cash is retained.
- ✓Yield check: 0.69% indicated — $0.40/qtr × 4 at the $230.50 close on Oct. 23, 2026. Real, earned yield for a single stock, not a special or a return of capital.
- ✓Dividend growth check: Raised 25% to $0.40 during 2026, the second consecutive annual increase per MarketBeat, with 5-year annualized growth of 12.20%. Growth, not current yield, is the point here.
What this grade doesn't say: It screens the dividend only — covered, real, compounding. It says nothing about valuation or price: a well-covered payer can still be overpriced, and its price can still fall.